17beta-hydroxysteroid dehydrogenase 13 inhibitor (Pfizer)

N/A

Report date: 2025/03/20 15:48:08
NME

Base Information

Drug Name17beta-hydroxysteroid dehydrogenase 13 inhibitor (Pfizer)
Drug Alias NameHSD17b13 inhibitor (Pfizer)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action17-beta-hydroxysteroid dehydrogenase 13 inhibitors
Targets17-beta-hydroxysteroid dehydrogenase 13
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A